Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)
Overview
Wegener’s granulomatosis, formally called Granulomatosis with Polyangiitis (GPA), is a rare, autoimmune vasculitis that inflames small‑ and medium‑sized blood vessels, especially those in the nose, sinuses, lungs, and kidneys. The inflammation can cause necrotizing (tissue‑destroying) granulomas—clusters of immune cells—that lead to organ damage if left untreated.
- Incidence: Approximately 3 – 5 new cases per million people per year in the United States and Europe.[1] CDC
- Prevalence: About 20 – 30 cases per million population.[2] Mayo Clinic
- Age & gender: Most commonly diagnosed between ages 40‑65; men and women are affected equally, though a slight male predominance is reported in some cohorts.[3] NIH
- Geography: Slightly higher rates in northern Europe and North America; rare in Asia and Africa.[4] WHO
Symptoms
GPA can involve multiple organ systems. Symptoms often appear in a “triad” (upper airway, lungs, kidneys), but any organ may be affected.
Upper respiratory tract (nose, sinuses, throat)
- Chronic sinusitis or recurrent sinus infections
- Persistent nasal congestion or crusting
- Bloody or crusted nasal discharge
- Ulceration of the nasal septum (saddle‑nose deformity)
- Ear pain, hearing loss, or otitis media
Lower respiratory tract (lungs)
- Dry cough
- Chest pain (pleuritic)
- Shortness of breath
- Hemoptysis (coughing up blood)
- Multiple nodules or infiltrates visible on chest imaging
Renal (kidneys)
- Hematuria (blood in urine)
- Proteinuria (protein in urine)
- Decreased urine output
- Rapid rise in serum creatinine—signs of acute kidney injury
General / systemic symptoms
- Unexplained fever
- Fatigue, malaise
- Weight loss
- Arthralgia or myalgia (joint/muscle aches)
- Skin lesions: palpable purpura, ulcers, or livedo reticularis
Other possible organ involvement
- Eye inflammation (conjunctivitis, scleritis, uveitis)
- Peripheral neuropathy (numbness, tingling)
- Gastrointestinal pain, bleeding, or ulceration
- Cardiac involvement (pericarditis, myocarditis)
Causes and Risk Factors
GPA is an autoimmune disease; the exact trigger is unknown, but research points to a complex interplay of genetics, environmental exposures, and immune dysregulation.
Immunologic factors
- ANCA antibodies: Over 90% of patients have anti‑proteinase 3 (PR3‑ANCA) antibodies, which are thought to activate neutrophils and damage vessel walls.
- Abnormal T‑cell responses and cytokine release (e.g., IL‑5, TNF‑α).
Genetic predisposition
- HLA‑DPB1*0401 and certain PRTN3 gene variants increase susceptibility.[5] NEJM
- Family clustering is rare but documented.
Environmental & occupational exposures
- Silica dust (mining, construction) – a known risk for ANCA‑vasculitis.[6] CDC
- Chronic nasal carriage of Staphylococcus aureus; colonization may provoke immune activation.
- Drug exposures (e.g., PTU, hydralazine) can induce ANCA-associated vasculitis that mimics GPA.
Who is at higher risk?
- Adults 40‑65 years old
- Smokers and individuals with occupational silica exposure
- Patients with a history of chronic sinus disease
- Those who are PR3‑ANCA positive (often correlates with more severe disease)
Diagnosis
Because GPA can mimic infections, malignancy, or other vasculitides, a systematic approach is essential.
Clinical assessment
- Detailed history of ENT, pulmonary, renal, and systemic symptoms.
- Physical exam focused on nasal ulcers, lung auscultation, skin lesions, and joint tenderness.
Laboratory tests
- ANCA testing: Indirect immunofluorescence (IIF) and ELISA for PR3‑ANCA (c‑ANCA) and MPO‑ANCA (p‑ANCA). PR3‑ANCA is present in ~70‑80% of GPA.
- Complete blood count (CBC) – anemia, leukocytosis.
- Renal panel – serum creatinine, BUN, electrolytes.
- Urinalysis – hematuria, proteinuria, casts.
- Inflammatory markers – ESR, CRP (often elevated).
Imaging
- Chest X‑ray: Nodules, cavitary lesions, infiltrates.
- CT scan (chest & sinuses): Better delineates pulmonary nodules, sinus opacification, and bony erosion.
- MRI: Used when orbital or CNS involvement is suspected.
Histopathology (biopsy)
- Definitive diagnosis requires tissue showing necrotizing granulomatous inflammation and vasculitis.
- Common sites: nasal mucosa, lung, kidney, or skin lesions.
- Biopsy should be performed early; a negative result does not entirely exclude GPA if clinical suspicion remains high.
Diagnostic criteria
The 2022 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria give points for:
- Positive PR3‑ANCA (score +5)
- Upper airway involvement (+3)
- Active pulmonary disease (+2)
- Glomerulonephritis (+2)
- Absence of eosinophilia (‑1)
A total score ≥ 5 classifies a patient as having GPA.
Treatment Options
Therapy aims to induce remission quickly, then maintain it while minimizing medication toxicity.
Induction therapy (rapid disease control)
- Glucocorticoids: Oral prednisone 1 mg/kg/day (max 60 mg) tapered over 4‑6 months. For severe disease, high‑dose IV methylprednisolone (500‑1000 mg/d for 3 days) may be used.
- Immunosuppressive agents:
- Rituximab: Anti‑CD20 monoclonal antibody. Standard regimen – 375 mg/m² weekly for 4 weeks or 1 g on days 0 and 14.
- Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2‑3 weeks) for 3‑6 months. Preferred when rapid control is needed, but carries fertility and bladder toxicity risks.
- Alternative agents: Methotrexate (≤ 25 mg/week) or mycophenolate mofetil for non‑life‑threatening disease.
Maintenance therapy (prevent relapse)
- Rituximab 500 mg IV every 6 months for 2‑4 years, or
- Azathioprine 2 mg/kg/day,
- Mycophenolate mofetil 1‑1.5 g twice daily, or
- Low‑dose glucocorticoids (≤ 5 mg prednisone daily) tapered as tolerated.
Adjunctive treatments
- Plasma exchange (PLEX): Considered for severe renal disease (eGFR < 15 mL/min/1.73 m²) or diffuse pulmonary hemorrhage; evidence from the PEXIVAS trial suggests modest benefit in selected patients.[7] NEJM
- Antibiotic prophylaxis: Trimethoprim‑sulfamethoxazole reduces risk of Staphylococcus aureus sinus colonization and may lower relapse rates.
- Bone health: Calcium, vitamin D, and bisphosphonates when long‑term steroids are used.
Lifestyle & supportive care
- Smoking cessation – improves pulmonary outcomes.
- Vaccinations: influenza, pneumococcal, COVID‑19 (non‑live vaccines preferred).
- Regular monitoring of blood counts, renal function, and ANCA levels.
- Psychosocial support – chronic disease can cause anxiety and depression.
Living with Wegener’s Granulomatosis
Although GPA is a serious disease, many patients achieve long‑term remission with therapy and lead active lives.
Self‑monitoring
- Keep a symptom diary (nasal crusting, cough, urine changes, joint pain).
- Check blood pressure and weight weekly.
- Report new or worsening hematuria, shortness of breath, or ear/nose bleeding promptly.
Medical follow‑up
- Rheumatology visits every 1‑3 months during induction, then every 3‑6 months for maintenance.
- Nephrology monitoring if kidneys were involved – serum creatinine and urine protein every 1‑2 months initially.
- Annual chest imaging for those with prior lung nodules.
Medication adherence
- Use pill organizers or smartphone reminders.
- Discuss side‑effects early; dose adjustments are often possible.
- Never stop steroids or immunosuppressants abruptly without physician guidance.
Lifestyle tips
- Balanced diet rich in antioxidants, adequate protein, and low sodium (protects kidney health).
- Gentle aerobic exercise (walking, swimming) as tolerated – improves stamina and bone density.
- Protect nasal passages: saline spray, humidifiers, and careful nasal hygiene to avoid trauma.
Emotional well‑being
- Join support groups (e.g., Vasculitis Foundation). Peer connections reduce isolation.
- Consider counseling or cognitive‑behavioral therapy if anxiety/depression arise.
- Educate family and coworkers about the disease to foster understanding.
Prevention
Because GPA is largely autoimmune, primary prevention is limited. However, risk reduction strategies are helpful.
- Avoid prolonged exposure to silica dust – use protective equipment if working in high‑risk occupations.
- Prompt treatment of chronic sinus infections; consider decolonization for persistent S. aureus carriers.
- Maintain good oral hygiene – periodontal disease may trigger systemic inflammation.
- Quit smoking and limit alcohol consumption to reduce overall vascular stress.
Complications
If untreated or inadequately controlled, GPA can cause irreversible organ damage.
- Kidney failure: Rapidly progressive glomerulonephritis may lead to end‑stage renal disease requiring dialysis or transplantation.
- Permanent lung damage: Fibrosis, cavitary lesions, or chronic bronchiectasis.
- Upper airway destruction: Saddle‑nose deformity, chronic sinusitis, or nasal perforation.
- Vascular events: Cerebral hemorrhage or ischemic stroke from vasculitis.
- Secondary infections: Immunosuppression increases risk for pneumonia, opportunistic fungi, or reactivation of latent TB.
- Medication toxicity: Cyclophosphamide‑induced bladder cancer, rituximab‑related hypogammaglobulinemia, steroid‑induced osteoporosis or diabetes.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden or severe shortness of breath, especially with coughing up blood.
- Acute kidney failure signs – sudden decrease in urine output, swelling of legs/face, or severe flank pain.
- Severe, uncontrolled nosebleeds or facial trauma causing rapid blood loss.
- High fever (> 102 °F / 38.9 °C) with chills and worsening pain.
- Chest pain that feels crushing, radiates to the back, or is accompanied by sweating.
- Neurologic changes – new weakness, numbness, vision loss, or severe headache.
These symptoms may signal life‑threatening pulmonary hemorrhage, renal crisis, or vasculitic stroke, which require immediate intervention.
References
- Centers for Disease Control and Prevention. “Vasculitis: Granulomatosis with Polyangiitis.” Updated 2023.
- Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” Accessed May 2026.
- National Institutes of Health. “ANCA-Associated Vasculitis Fact Sheet.” 2022.
- World Health Organization. “Rare Diseases: Epidemiology.” 2021.
- Kallenberg CG. “Pathogenesis of ANCA-associated vasculitis.” New England Journal of Medicine. 2020;382:1158‑1170.
- U.S. Occupational Safety and Health Administration. “Silica Exposure and Vasculitis.” 2022.
- McAdoo SP, et al. “Plasma Exchange in ANCA-Associated Vasculitis (PEXIVAS).” NEJM. 2020;382:1206‑1218.